TY - JOUR AU - Torre, L. A. AU - Bray, F. AU - Siegel, R. L. AU - Ferlay, J. AU - Lortet-Tieulent, J. AU - Jemal, A. PY - 2015 DA - 2015// TI - Global cancer statistics, 2012 JO - CA Cancer J Clin VL - 65 UR - https://doi.org/10.3322/caac.21262 DO - 10.3322/caac.21262 ID - Torre2015 ER - TY - JOUR AU - Cheng, A. L. AU - Kang, Y. K. AU - Chen, Z. AU - Tsao, C. J. AU - Qin, S. AU - Kim, J. S. PY - 2009 DA - 2009// TI - Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial JO - Lancet Oncol VL - 10 UR - https://doi.org/10.1016/S1470-2045(08)70285-7 DO - 10.1016/S1470-2045(08)70285-7 ID - Cheng2009 ER - TY - JOUR AU - Llovet, J. M. AU - Ricci, S. AU - Mazzaferro, V. AU - Hilgard, P. AU - Gane, E. AU - Blanc, J. F. PY - 2008 DA - 2008// TI - Sorafenib in advanced hepatocellular carcinoma JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0708857 DO - 10.1056/NEJMoa0708857 ID - Llovet2008 ER - TY - STD TI - Terashima T, Yamashita T, Iida N, Yamashita T, Nakagawa H, Arai K, et al. Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy. Hepatol Res. 2014; https://doi.org/10.1111/hepr.12436. ID - ref4 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2011 DA - 2011// TI - Hallmarks of cancer: the next generation JO - Cell VL - 144 UR - https://doi.org/10.1016/j.cell.2011.02.013 DO - 10.1016/j.cell.2011.02.013 ID - Hanahan2011 ER - TY - JOUR AU - Straussman, R. AU - Morikawa, T. AU - Shee, K. AU - Barzily-Rokni, M. AU - Qian, Z. R. AU - Du, J. PY - 2012 DA - 2012// TI - Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion JO - Nature VL - 487 UR - https://doi.org/10.1038/nature11183 DO - 10.1038/nature11183 ID - Straussman2012 ER - TY - JOUR AU - Yamashita, T. AU - Wang, X. W. PY - 2013 DA - 2013// TI - Cancer stem cells in the development of liver cancer JO - J Clin Invest VL - 123 UR - https://doi.org/10.1172/JCI66024 DO - 10.1172/JCI66024 ID - Yamashita2013 ER - TY - JOUR AU - Horwitz, E. AU - Stein, I. AU - Andreozzi, M. AU - Nemeth, J. AU - Shoham, A. AU - Pappo, O. PY - 2014 DA - 2014// TI - Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment JO - Cancer Discov VL - 4 UR - https://doi.org/10.1158/2159-8290.CD-13-0782 DO - 10.1158/2159-8290.CD-13-0782 ID - Horwitz2014 ER - TY - JOUR AU - Arao, T. AU - Ueshima, K. AU - Matsumoto, K. AU - Nagai, T. AU - Kimura, H. AU - Hagiwara, S. PY - 2012 DA - 2012// TI - FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma JO - Hepatology VL - 57 UR - https://doi.org/10.1002/hep.25956 DO - 10.1002/hep.25956 ID - Arao2012 ER - TY - JOUR AU - Llovet, J. M. AU - Peña, C. E. AU - Lathia, C. D. AU - Shan, M. AU - Meinhardt, G. AU - Bruix, J. PY - 2012 DA - 2012// TI - Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-11-2175 DO - 10.1158/1078-0432.CCR-11-2175 ID - Llovet2012 ER - TY - JOUR AU - Yamashita, T. AU - Arai, K. AU - Sunagozaka, H. AU - Ueda, T. AU - Terashima, T. AU - Mizukoshi, E. PY - 2011 DA - 2011// TI - Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma JO - Oncology VL - 81 UR - https://doi.org/10.1159/000334439 DO - 10.1159/000334439 ID - Yamashita2011 ER - TY - JOUR AU - Budhu, A. AU - Forgues, M. AU - Ye, Q. H. AU - Jia, H. L. AU - He, P. AU - Zanetti, K. A. PY - 2006 DA - 2006// TI - Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment JO - Cancer Cell VL - 10 UR - https://doi.org/10.1016/j.ccr.2006.06.016 DO - 10.1016/j.ccr.2006.06.016 ID - Budhu2006 ER - TY - JOUR AU - Ezzoukhry, Z. AU - Louandre, C. AU - Trécherel, E. AU - Godin, C. AU - Chauffert, B. AU - Dupont, S. PY - 2012 DA - 2012// TI - EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib JO - Int J Cancer VL - 131 UR - https://doi.org/10.1002/ijc.27604 DO - 10.1002/ijc.27604 ID - Ezzoukhry2012 ER - TY - JOUR AU - Wilhelm, S. M. AU - Adnane, L. AU - Newell, P. AU - Villanueva, A. AU - Llovet, J. M. AU - Lynch, M. PY - 2008 DA - 2008// TI - Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling JO - Mol Cancer Ther VL - 7 UR - https://doi.org/10.1158/1535-7163.MCT-08-0013 DO - 10.1158/1535-7163.MCT-08-0013 ID - Wilhelm2008 ER -